This single domain antibody binding to PCSK9 is capable of lowering low-density lipoprotein-cholesterol (LDL-C) levels. It can be potentially used for the treatment of cardiovascular disorders.
Figure 1 The effect of sdAbs on wild type (WT) PCSK9-induced LDLR degradation.
Naive HuH7 cells were incubated with 1 ug/mL of purified WT PCSK9 for 24 h in the absence (Control) or presence of 100 μg/mL of various sdAbs to PCSK9. The cells were then detached and analyzed by flow cytometry for cell surface LDLR.
Figure 2 The effect of sdAbs on WT PCSK9-induced LDLR degradation.
Naive HuH7 cells were incubated with 1 μg/mL of purified WT PCSK9 for 24 h in the absence (Control) or presence of 50 μg/mL of various sdAbs to PCSK9. The cells were then detached and analyzed by flow cytometry for cell surface LDLR.
Figure 3 The effect of sdAbs on WT PCSK9-induced LDLR degradation.
Flow cytometry of cell surface LDLR (level of LDLR Expression.
Figure 4 The effect of sdAbs on WT PCSK9-induced LDLR degradation.
Naive HuH7 cells were incubated for 18 h in the absence [Cnt(−)] or presence of 0.7 ug/ml (˜9 nM) WT PCSK9 protein alone [Cnt(+)] or mixed with 50 ug/ml (˜3 uM) of various purified llama sdAbs.
Figure 5 The effect of sdAbs on the gain-of-function PCSK9-D374Y-induced LDLR degradation.
Naive Huh7 cells were incubated for 18 h in the absence [Cnt(−)] or presence of 0.5 ug/ml (˜6 nM) PCSK9-D374Y protein alone [Cnt(+)] or mixed with 50 ug/ml (˜3 uM) of various purified llama sdAbs.
Figure 6 The effect of sdAbs on PCSK9-D374Y gain-of-function mutation-induced LDLR degradation as measured with Dil-LDL uptake assay.
Naive HepG2 cells were incubated for 4 h in the absence [Cnt(−)] or presence of 0.5 μg/mL purified PCSK9-mutant D374Y [Cnt(+)]. The addition of 50 μg/mL of various sdAbs is indicated below.
Figure 7 The effect of sdAbs on the gain-of-function PCSK9-D374Y-induced LDLR degradation.
Naive Huh7 cells were incubated for 18 h in the absence [Cnt(−)] or presence of 0.5 ug/ml (˜6 nM) PCSK9-D374Y protein alone [Cnt(+)] or mixed with increasing concentrations of PKE2 sdAbs.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NABL-097 | Recombinant Anti-human PCSK9 VHH Single Domain Antibody | WB, ELISA, IHC, FC, FuncS | Llama VHH |
TAB-0081CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0081CL-VHH) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0082CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0082CL-VHH) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0083CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0083CL-VHH) | FuncS, Inhib, FC, WB | Single domain antibody |
TAB-0084CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0084CL-VHH) | FuncS, Inhib, FC, WB | Single domain antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H10 | Anti-Human PCSK9 Recombinant Antibody (Bococizumab) | WB, FC, IP, ELISA, Neut, FuncS, IF | IgG2 - kappa |
TAB-H59 | Anti-Human PCSK9 Recombinant Antibody (Ralpancizumab) | Neut, ELISA, IF, IP, FuncS, FC, ICC | IgG2 - kappa |
TAB-764CL | Human Anti-PCSK9 Recombinant Antibody (TAB-764CL) | ELISA | Human IgG |
TAB-0020CL | Anti-Human PCSK9 Recombinant Antibody (LPD1282/LPD1462 {i.e., antibody 1 F11)) | LDL-c uptake assay | Humanized Antibody |
TAB-0020CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (LPD1282/LPD1462 {i.e., antibody 1 F11)) | LDL-c uptake assay | Humanized Antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBL-294 | Human Anti-PCSK9 Recombinant Antibody (clone mAb1); scFv Fragment | WB, Block, FuncS | Human scFv |
HPAB-0511-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0511-FY-S(P)) | Neut | Human scFv |
HPAB-0512-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0512-FY-S(P)) | Neut | Human scFv |
HPAB-0513-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0513-FY-S(P)) | Neut | Human scFv |
HPAB-0724YY-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0724YY-S(P)) | ELISA | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
PABZ-101 | Human Anti-PCSK9 Recombinant Antibody (clone 1D05) | ELISA, WB, Neut | Human IgG2 |
HPAB-0234-YC | Mouse Anti-PCSK9 Recombinant Antibody (HPAB-0234-YC) | ELISA, FuncS | Mouse IgG |
PABC-505 | Human Anti-PCSK9 Recombinant Antibody (clone 5E11) | WB, IP, ELISA, IF, Inhib | Human IgG1, λ |
HPAB-2454LY | Human Anti-PCSK9 Recombinant Antibody (HPAB-2454LY) | ELISA, Inhib | Chimeric (mouse/human) IgG |
HPAB-2455LY | Human Anti-PCSK9 Recombinant Antibody (clone 8D8F) | ELISA | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0956CL | Anti-Human PCSK9 Recombinant Antibody (m7F8) | ELISA | |
TAB-0960CL | Anti-Human PCSK9 Recombinant Antibody (Ab1) | ELISA | Rabbit mAb |
TAB-0956CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (m7F8) | ELISA | |
TAB-0960CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (Ab1) | ELISA | Rabbit mAb |
TAB-0956CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (m7F8) | ELISA |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0959CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0959CL) | ELISA, FC | Human antibody |
TAB-0959CL-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (TAB-0959CL-S(P)) | ELISA, FC | Human scFv |
TAB-0953CL-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (TAB-0953CL-F(E)) | ELISA | Human Fab |
TAB-0954CL-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (TAB-0954CL-F(E)) | WB | Human Fab |
TAB-0959CL-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (TAB-0959CL-F(E)) | ELISA, FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1826CQ | Recombinant Human Anti-PCSK9 Antibody, Unconjugated | Neut | IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2618 | Hi-Affi™ Recombinant Rabbit Anti-PCSK9 Monoclonal Antibody (DS2618AB) | WB | IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-667-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-667-FY-F(E)) | Inhib | Human Fab |
HPAB-668-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-668-FY-F(E)) | Inhib | Human Fab |
HPAB-0240-WJ-F(E) | Mouse Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-0240-WJ-F(E)) | ELISA | Mouse Fab |
HPAB-0241-WJ-F(E) | Mouse Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-0241-WJ-F(E)) | ELISA | Mouse Fab |
HPAB-0242-WJ-F(E) | Mouse Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-0242-WJ-F(E)) | ELISA | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-758 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Lodelcizumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
AFC-TAB-H10 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS | ADCC enhanced antibody |
AFC-TAB-H59 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Ralpancizumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-H31 | Afuco™ Anti-PCSK9 Recombinant Antibody (AFC-TAB-H31), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | Human IgG1, λ |
There are currently no Customer reviews or questions for TAB-0080CL-VHH. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.